Deepening Collaboration for Expanded Clinical Trials and Accelerated CDx Launch

On March 30, medical artificial intelligence (AI) company Lunit announced that it has entered into a strategic collaboration with global clinical research organization (CRO) CellCarta to accelerate the commercialization of AI biomarker-based companion diagnostics (CDx).


In September of last year, the two companies formed a partnership to apply Lunit's AI biomarker, "Lunit Scope," to CellCarta's global clinical trial environment. The latest collaboration further advances this initiative, focusing on the development and launch preparation of CDx and supporting their global commercialization.

Lunit and CellCarta Join Forces for Commercialization of AI Biomarker Companion Diagnostics View original image

The companies have agreed to integrate Lunit Scope into CellCarta's clinical workflow to support the following: establishing biomarker strategies, quantitative analysis of immunohistochemistry (IHC), immunophenotyping analysis, clinical trial testing, and preparation for CDx. By doing so, they aim to help pharmaceutical companies enter clinical trials more quickly and expedite CDx launch timelines, thereby supporting the future global commercialization of AI-based biomarker solutions. Additionally, the two companies plan to introduce pilot programs in clinical environments worldwide to expand the use of AI throughout the clinical trial process.


Dusty Tenney, CEO of CellCarta, said, "Pharmaceutical companies want speed and flexibility of choice without compromising quality. By combining CellCarta's global CDx execution capabilities with Lunit's AI solutions, we aim to help pharmaceutical companies advance new drug development quickly."



Beomseok Seo, CEO of Lunit, stated, "For the adoption of AI in the global pharmaceutical and biotech industry, scalability that can be applied to real clinical settings is crucial. Through our collaboration with CellCarta, we will build an integrated AI model to support clinical trials and rapidly drive the commercialization of companion diagnostics."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing